To get in touch with XenTech, simply fill out the form below.
Subscribe to Supplier
High demand for oncology expertise drives XenTech expansion
Evry, France: – Rising demand for preclinical oncology expertise is fuelling growth at biotech and contract research organisaton XenTech.
The French-based laboratory says it is hiring new employees and developing new commercial and academic collaborations in response to high and growing demand among clients.
It has also increased capacity at its animal care and breeding facility by 50 per cent.
XenTech has made five new research and management hires since the beginning of 2015. It has also entered new collaborative research projects with Institut Curie, Centre Jean Perrin, Gustave Roussy, Oregon Health & Sciences University and Vanderbilt University Medical Center.
It has also entered new partnerships with Massachusetts-based CRO Cambridge Biomedical, and French-based histology services specialist Histalim.
Founded in 2006, XenTech has shown consistent year on year growth but Chief Operating Officer Pascal Leraud says the pace of expansion has quickened noticeably over the past year.
“We are starting to reap the rewards from ever-growing trust in the XenTech brand as a guarantee of preclinical oncology expertise as well as the time and effort expended in growing our portfolio of patient-derived tumor xenografts (PDX) models,” said Mr. Leraud.
“Our clients have come to understand that we are absolutely committed to ensuring high quality and availability, as well as constantly maintaining our expertise at the leading edge of contract research in oncology,” said Xentech’s COO.
XenTech is an innovative biotech/CRO company specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.
XenTech has assembled one of the world’s most impressive collections of PDX models that are extensively characterized and associated to molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine. XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.
XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and it’s extremely experienced scientific team.